REGENERATIVE MEDICINE
THERAPIES FOR KIDNEY DISEASE
THERAPIES FOR KIDNEY DISEASE
REGENERATIVE MEDICINE
THERAPIES FOR KIDNEY DISEASE
THERAPIES FOR KIDNEY DISEASE
Advanced cell and extracellular vesicles (EVs) based therapies to minimize the need for dialysis & renal transplantation in kidney disease patients.
LIVEKIDNEY.BIO is a biotechnology company developing proprietary cell-derived delivery platform, based on sustained release hydrogel formulations combined with AI-enabled data analytics, that has the unique potential to improve patients’ health and life and to reduce the escalating economic burden of kidney disease on society.
We are aiming to prevent the progression of kidney disease thereby allowing kidney patients to live longer, better quality, and more productive lives.
PRODUCTS:
PROPRIETARY CELL-DERIVED THERAPY DELIVERY PLATFORM
Novel AI-based cell-derived therapy for ameliorating kidney function of CKD patients & general medical conditions of Lupus patients. Our promising pipeline of cell therapy-based products comprised of proprietary injectable hydrogel formulations delivered in an exclusive and unique administration route are being developed.
CKD DISEASE AND MARKET
Over 850M CKD patients WW. Devastating progressive disease with no cure. At least 4M patients on dialysis, only one-third will survive 5 years dialysis treatment. >$65 Billion annual expenses on CKD care.
End Stage Kidney Disease (ESKD) is increasing rapidly worldwide as a result of aging, diabetes, hypertension, obesity, and lack of cure.
There is a pressing medical need for disruptive treatment before reaching the stage of Renal Replacement Therapy (dialysis or transplantation) by ameliorating kidney function in advanced kidney disease patients.
CKD DISEASE AND MARKET
Over 850M CKD patients WW. Devastating progressive disease with no cure. At least 4M patients on dialysis, only one-third will survive 5 years dialysis treatment. >$65 Billion annual expenses on CKD care.
End Stage Kidney Disease (ESKD) is increasing rapidly worldwide as a result of aging, diabetes, hypertension, obesity, and lack of cure.
There is a pressing medical need for disruptive treatment before reaching the stage of Renal Replacement Therapy (dialysis or transplantation) by ameliorating kidney function in advanced kidney disease patients.
LUPUS DISEASE AND MARKET
5 M Lupus patients WW. Auto-immune disease that compromises quality of life and patients’ general wellbeing. Overall Lupus market is estimated around $1B with an expected 5.6% annual growth rate.
Lupus Nephritis is a particular severe kidney disease manifestation of Lupus, occurs in 60% of cases and correlates with a higher mortality rate. The main goal of the management of LN is to avoid Advanced Chronic Kidney Disease (ACKD).
Lupus predominantly affects women of childbearing age, with 10-fold higher prevalence in females than in males.
MANAGEMENT TEAM
Dr. Alon Yaar, DVM, MBA: Biotech Executive Leader
Former CEO/COO of NeuroDerm (NASDAQ:NDRM) acquired by Mitsubishi Tanabe in 2017 in a $1.2 billion deal.
Dr. Masha Simanovsky, Ph.D.: R&D Leader
Expert in cell therapy and Extracellular Vesicles, Former Project Manager at Solubest Ltd.
Dr. Shimon Amselem, Ph.D.: Formulations Leader
Expert in implantable biodegradable polymers. Significant contributions to five approvals by the FDA and four IND in Phase II/III clinical trials.
Avraham Hermon, MA: IP Leader
Israeli Patent Attorney and a US Patent Agent. Former Senior Manager at Teva Pharmaceutical.
Dr Nadya Lisovoder, MD: Clinical Leader
Regulatory expert and a clinical adviser with a vast experience in clinical studies in the pharma industry.
ADVISORY BOARD
Prof. Chaim Putterman
Professor of Medicine & Immunology at the Albert Einstein College of Medicine
Prof. Lilach O. Lerman
Professor of Medicine at The Renovascular Disease Research Laboratory, Mayo Clinic
Dr. Abeer Suleiman
Holy Family Hospital, Nazareth, Israel
Prof. Gary Gilkeson
Professor of Medicine, Associate Dean for Faculty Affairs and Faculty Development, Medical University of South Carolina
TO LEARN MORE, OR PARTNER WITH LIVEKIDNEY,
CONTACT US TODAY!
CONTACT
STRATEGIC PARTNERSHIPS
Mayo Clinic
Medical University of South Carolina
Holy family hospital, Nazareth
Medical University of South Carolina
Holy family hospital, Nazareth
ADVANCED CELL THERAPY
Aiming to prevent the progression of Chronic Kidney Disease.
Stage: clinical stage, Phase II: 2022
Stage: clinical stage, Phase II: 2022
